Pharmacological studies with a nonpeptidic, delta-opioid (-)-(1R,5R,9R)-5,9-dimethyl-2'-hydroxy-2-(6-hydroxyhexyl)-6,7-benzomorphan hydrochloride ((-)-NIH 11082).

Pharmacological studies with a nonpeptidic, delta-opioid (-)-(1R,5R,9R)-5,9-dimethyl-2'-hydroxy-2-(6-hydroxyhexyl)-6,7-benzomorphan hydrochloride ((-)-NIH 11082). Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Pharmacological studies with a nonpeptidic, delta-opioid (-)-(1R,5R,9R)-5,9-dimethyl-2'-hydroxy-2-(6-hydroxyhexyl)-6,7-benzomorphan hydrochloride ((-)-NIH 11082). Abstract Text:

Mario D Aceto,Everette L May,Louis S Harris,Edward R Bowman,Charles D Cook,

In the search for a selective delta-opioid receptor agonist, (-)-(1R,5R,9R)-5,9-dimethyl-2'-hydroxy-2-(6-hydroxyhexyl)-6,7-benzomorphan hydrochloride ((-)-NIH 11082) and the (+)-enantiomer were synthesized and tested. (-)-NIH 11082 displayed antinociceptive activity in the paraphenylquinone test (PPQ test) in male ICR mice [ED50=1.9 (0.7-5.3) mg/kg, s.c.] and showed little, if any, activity in the tail-flick and hot-plate assays. The (+)-enantiomer was essentially inactive indicating stereoselectivity. Opioid receptor subtype characterization studies indicated that naltrindole, a delta-opioid receptor antagonist, was potent versus the ED80 of (-)-NIH 11082 in the PPQ test [AD50=0.75 (0.26-2.20) mg/kg, s.c]. beta-Funaltrexamine and nor-binaltorphimine, selective mu- and kappa-receptor antagonists, respectively, were inactive versus the ED80 of (-)-NIH 11082. In rats with inflammation-induced pain, (-)-NIH 11082 produced antihyperalgesic effects that were attenuated by naltrindole. In morphine-dependent rhesus monkeys of both sexes, (-)-NIH 11082 neither substituted for morphine nor exacerbated withdrawal signs in the dose range of 4.0 to 32.0 mg/kg, s.c. Neither convulsions nor other overt behavioral signs were observed in any of the species tested. The results indicate that (-)-NIH 11082 has delta-opioid receptor properties.

Pharmacological studies with a nonpeptidic, delta-opioid (-)-(1R,5R,9R)-5,9-dimethyl-2'-hydroxy-2-(6-hydroxyhexyl)-6,7-benzomorphan hydrochloride ((-)-NIH 11082). Publishing Authors By Initials

MD Aceto,EL May,LS Harris,ER Bowman,CD Cook,

For similar disorders of environmental origin: substance-related disorders: substance withdrawal syndrome research abstracts see: disorders of environmental origin: substance-related disorders: substance withdrawal syndrome research

PUBMED ID PMID:

MEDLINE DATE:

Pharmacological studies with a nonpeptidic, delta-opioid (-)-(1R,5R,9R)-5,9-dimethyl-2'-hydroxy-2-(6-hydroxyhexyl)-6,7-benzomorphan hydrochloride ((-)-NIH 11082). Journal Published:

PUBLICATION TYPE: Research Support, N.I.H., Extr

Journal: European journal of pharmacology

VOLUME: 566

Page Numbers: 88-93

Journal Abbreviation: Eur. J. Pharmacol.

ISSN: 0014-2999

DAY: 19

MONTH: 03

YEAR: 2007

Pharmacological studies with a nonpeptidic, delta-opioid (-)-(1R,5R,9R)-5,9-dimethyl-2'-hydroxy-2-(6-hydroxyhexyl)-6,7-benzomorphan hydrochloride ((-)-NIH 11082). Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 1254354

Pharmacological studies with a nonpeptidic, delta-opioid (-)-(1R,5R,9R)-5,9-dimethyl-2'-hydroxy-2-(6-hydroxyhexyl)-6,7-benzomorphan hydrochloride ((-)-NIH 11082). Keywords Mesh Terms:

KEYWORDS: Substance Withdrawal Syndrome

MESH TERMS: drug therapy

Chemical & Substance for Abstract: Pharmacological studies with a nonpeptidic, delta-opioid (-)-(1R,5R,9R)-5,9-dimethyl-2'-hydroxy-2-(6-hydroxyhexyl)-6,7-benzomorphan hydrochloride ((-)-NIH 11082). Information

Substance Name: Naltrexone

Registry Number: 16590-41-3

Grant and Affiliation Information for Pharmacological studies with a nonpeptidic, delta-opioid (-)-(1R,5R,9R)-5,9-dimethyl-2'-hydroxy-2-(6-hydroxyhexyl)-6,7-benzomorphan hydrochloride ((-)-NIH 11082).

AFFILIATION: Department of Pharmacology and Toxicology, School of Medicine, Virginia Commonwealth University, Richmond, VA 23298-0613, USA. mdaceto@vcu.edu

Country: Netherlands

AGENCY: United States NIDA

GRANT: DA 8-8088

ACRONYM: DA

MEDLINETA: Eur J Pharmacol

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Pharmacological studies with a nonpeptidic, delta-opioid --1R,5R,9R-5,9-dimethyl-2'-hydroxy-2-6-hydroxyhexyl-6,7-benzomorphan hydrochloride --NIH 11082 Related Publications

• 449.
• 5-HTTLPR Genotype-Specific Phenotype in Children and Adolescents With Autism.
• A proposed proton shuttle mechanism for saccharopine dehydrogenase from Saccharomyces cerevisiae.
• A prospective, open-label trial of memantine in the treatment of cognitive, behavioral, and memory dysfunction in pervasive developmental disorders.
• An intracrine view of angiogenesis.
• Association of dopamine transporter genotype with disruptive behavior disorders in an eight-year longitudinal study of children and adolescents.
• Association of the oxytocin receptor gene (OXTR) in Caucasian children and adolescents with autism.
• Beta-arrestins 1 and 2 differentially regulate LPS-induced signaling and pro-inflammatory gene expression.
• Characterization and in vitro degradation of salicylate-derived poly(anhydride-ester microspheres).
• Chronic glaucoma case finding and treatment in rural Africa: some questions and answers.
• Complete kinetic mechanism of homoisocitrate dehydrogenase from Saccharomyces cerevisiae.
• Conformational analysis of the cis- and trans-adducts of the Pictet - Spengler reaction. Evidence for the structural basis for the C(1) - N(2) scission process in the cis- to trans-isomerization.
• Differential regulation of lipopolysaccharide and Gram-positive bacteria induced cytokine and chemokine production in splenocytes by Galphai proteins.
• Effect of Medicaid Managed Care on racial disparities in health care access.
• First enantiospecific total synthesis of the important biogenetic intermediates, (+)-polyneuridine and (+)-polyneuridine aldehyde, as well as 16-epi-vellosimine and macusine A.
• Genes expressed by both mesangial cells and bone marrow-derived cells underlie genetic susceptibility to crescentic glomerulonephritis in the rat.
• How to improve the outcome of cataract surgery.
• ITGB3 shows genetic and expression interaction with SLC6A4.
• Improving point predictions of random effects for subjects at high risk.
• Imputation strategies for blood pressure data nonignorably missing due to medication use.
• Monitoring cataract surgical outcomes: 'hand written' registration method.
• Oxidation artifacts in the electrospray mass spectrometry of Abeta Peptide.
• Pharmacological studies with a nonpeptidic, delta-opioid (-)-(1R,5R,9R)-5,9-dimethyl-2'-hydroxy-2-(6-hydroxyhexyl)-6,7-benzomorphan hydrochloride ((-)-NIH 11082).
• Preventing alcohol-exposed pregnancies.
• Remarkably mild and efficient intramolecular Friedel-Crafts cyclization catalyzed by In(III).
• The effects of dietary protein on age and weight at the onset of puberty in Brown Swiss and Zebu heifers in the tropics.
• The molecular mechanisms responsible for resistance in plant-pathogen interactions of the gene-for-gene type function more broadly than previously imagined.
• Tremor/ataxia syndrome and fragile X premutation: diagnostic caveats.
• Walking stride variability on different walking surfaces: 849: june 1 2:00 PM - 2:15 PM.
• rasiRNAs, DNA damage, and embryonic axis specification.